Apogee Therapeutics (APGE)
NASDAQ:APGE
Want to see APGE full AI Analyst Report?
APGE Stock Chart & Stats
$89.32
-$0.82(-1.65%)
At close: 4:00 PM EST
$89.32
-$0.82(-1.65%)
Day’s Range― - ―
52-Week Range$31.38 - $89.69
Previous CloseN/A
Volume109.80K
Average Volume (3M)1.09M
Market Cap
$6.21B
Enterprise Value$4.88B
Total Cash (Recent Filing)$730.19M
Total Debt (Recent Filing)$8.85M
Price to Earnings (P/E)―
Beta1.13
Next Earnings
May 18, 2026EPS Estimate
-1.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.03
Shares Outstanding55,998,604
10 Day Avg. Volume633,592
30 Day Avg. Volume1,093,991
Financial Highlights & Ratios
PEG Ratio-0.64
Price to Book (P/B)5.07
Price to Sales (P/S)0.00
P/FCF Ratio-19.69
Enterprise Value/Market Cap0.79
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-17.56
Forecast
1Y Price Target
$120.64Price Target Upside35.06% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14
EPS Forecast (FY)-4.63
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical DurabilityPhase II maintenance data showed responses deepened across three-month and six-month dosing regimens, indicating durable efficacy that could distinguish the therapy from standard treatments.
Dosing ConvenienceMaintenance dosing every few months may offer a clear convenience advantage for patients and prescribers compared with more frequent injection schedules, supporting stronger commercial uptake.
Regulatory PathwayAnalyst increased the estimated probability of regulatory and commercial success and cited plans to enter pivotal phase three trials with regulatory engagement, suggesting a clearer path toward potential approval and launch.
Bears Say
Competitive PressureMultiple companies developing long-acting IL-13 therapies may capture market share and challenge commercial prospects despite the drug's dosing advantages.
Safety Data TransparencyLack of detailed adverse event rates, particularly for eye inflammation, makes it difficult to benchmark safety against competitors and could weaken the drug's positioning if detailed data are unfavorable.
Safety EventsConjunctivitis occurred with notable frequency and led some patients to stop treatment, which could raise safety concerns among clinicians and risk impacting adoption.
Apogee Therapeutics News
APGE FAQ
What was Apogee Therapeutics’s price range in the past 12 months?
Apogee Therapeutics lowest stock price was $31.38 and its highest was $89.69 in the past 12 months.
What is Apogee Therapeutics’s market cap?
Apogee Therapeutics’s market cap is $6.21B.
When is Apogee Therapeutics’s upcoming earnings report date?
Apogee Therapeutics’s upcoming earnings report date is May 18, 2026 which is in 32 days.
How were Apogee Therapeutics’s earnings last quarter?
Apogee Therapeutics released its earnings results on Mar 02, 2026. The company reported -$1.03 earnings per share for the quarter, beating the consensus estimate of -$1.045 by $0.015.
Is Apogee Therapeutics overvalued?
According to Wall Street analysts Apogee Therapeutics’s price is currently Undervalued.
Does Apogee Therapeutics pay dividends?
Apogee Therapeutics does not currently pay dividends.
What is Apogee Therapeutics’s EPS estimate?
Apogee Therapeutics’s EPS estimate is -1.08.
How many shares outstanding does Apogee Therapeutics have?
Apogee Therapeutics has 55,998,604 shares outstanding.
What happened to Apogee Therapeutics’s price movement after its last earnings report?
Apogee Therapeutics reported an EPS of -$1.03 in its last earnings report, beating expectations of -$1.045. Following the earnings report the stock price went up 1.307%.
Which hedge fund is a major shareholder of Apogee Therapeutics?
Currently, no hedge funds are holding shares in APGE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Apogee Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$120.64 (35.06% Upside)
$120.64 (35.06% Upside)
Blogger Sentiment
Bullish
APGE Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 993.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $133.5M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.9%
Last 30 Days ▲ 12.2%
Last 30 Days ▲ 12.2%
Technicals
SMA
Positive
20 days / 200 days
Momentum
165.83%
12-Months-Change
Fundamentals
Return on Equity
-36.77%
Trailing 12-Months
Asset Growth
24.30%
Trailing 12-Months
Company Description
Apogee Therapeutics
Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs include APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. The company was founded in 2022 and is based in Waltham, Massachusetts.
APGE Stock 12 Month Forecast
Average Price Target
$120.64
▲(35.06% Upside)
Technical Analysis
Agios Pharma
―
Ocular Therapeutix
―
Galapagos
―
Liquidia Technologies
―
IDEAYA Biosciences
―
Ownership Overview
Currently, No data available
---